The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer.

KRAS mutations are high prevalence oncogenic drivers for multiple cancers. With the advent of new classes of KRAS inhibitors that are showing meaningful clinical activity, research is now turning to questions of optimal combinations of therapies for specific indications, as many patients with KRAS G...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Angela Abdollahi, Margaret Favata, Michael Weber, Valerie Roman, Rodrigo Hess, Kayla Hammond, Matthew R Farren, Mike Schaffer, Aidan Gilmartin, Hui Wang, Jonathan Rios-Doria, Alejandro Amador-Arjona
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Public Library of Science (PLoS) 2025-01-01
Colecção:	PLoS ONE
Acesso em linha:	https://doi.org/10.1371/journal.pone.0327588
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!